Oncology News Central (ONC)“Resoundingly” Negative Phase 3 Lung Cancer Trial Has “Concerning” Findings

⚠️ Rare but High Risk Safety Event

Thoracic radiotherapy has demonstrated benefit in selected small cell lung cancer settings, and retrospective data suggested potential synergy with chemoimmunotherapy. This phase 3 European study evaluated whether adding concurrent thoracic radiotherapy to durvalumab-based chemoimmunotherapy could improve outcomes in extensive-stage disease.

Clinical Considerations

• Concurrent thoracic radiotherapy did not improve overall survival, with median survival of 10.0 versus 11.1 months.
• Progression-free survival remained identical at 5.1 months in both treatment groups.
• Adverse events occurred more frequently with radiotherapy, affecting 87.8% versus 69.9% of patients.
• Investigators reported more treatment-related deaths and substantially higher rates of esophagitis in the radiotherapy arm.

Practice Applications

• Avoid assuming radiotherapy-immunotherapy synergy translates from limited-stage to extensive-stage disease.
• Interpret negative phase 3 results alongside observed safety concerns.
• Recognize increased toxicity risks when evaluating multimodality treatment strategies.
• Monitor emerging frontline studies evaluating alternative immunotherapy combinations.